Disease Domain | Count |
---|---|
Neoplasms | 2 |
Nervous System Diseases | 1 |
Endocrinology and Metabolic Disease | 1 |
Top 5 Drug Type | Count |
---|---|
Monoclonal antibody | 1 |
Small molecule drug | 1 |
Top 5 Target | Count |
---|---|
CLDN18.2(Claudin 18.2) | 1 |
AR(Androgen Receptor) | 1 |
Target |
Mechanism CLDN18.2 inhibitors [+2] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. JP |
First Approval Date26 Mar 2024 |
Target |
Mechanism AR antagonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date31 Aug 2012 |
Target |
Mechanism CD2 inhibitors |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhaseWithdrawn |
First Approval Ctry. / Loc. US |
First Approval Date30 Jan 2003 |
Start Date01 Apr 2016 |
Sponsor / Collaborator |
Start Date18 Jul 2013 |
Sponsor / Collaborator |
Start Date01 Oct 2012 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Enzalutamide ( AR ) | Castration-sensitive prostate cancer More | Approved |
Zolbetuximab ( CLDN18.2 ) | Neoplasms More | NDA/BLA |
Alefacept ( CD2 ) | Psoriasis More | Withdrawn |